Rexgenero treats first patients in CLI trial
London, UK-based Rexgenero has reached a major milestone in treating the first patient in a late-stage trial with its lead product, cell therapy REX-001.
Read More
Tag: Rexgenero
Rexgenero wins £1.4m grant from Innovate UK
London, UK-based Rexgenero has secured with partners £1.4 million in funding for a £1.8 million project from the UK’s innovation agency Innovate UK, for an industrial research project on the commercial manufacture of its product REX-001.
Read More
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
